Preclinical trials with both EGFR/EGFRvIII104 and HER2105 CAR-NK have demonstrated enhanced cytotoxicity against glioblastoma cells in vitro and resulted in increased tumor control and survival in animal models. This evidence concerns the gene EGFR and glioblastoma.